Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hikma Pharmaceuticals Plc Sees To Meet FY 2013 Revenue Guidance


Friday, 8 Nov 2013 02:00am EST 

Hikma Pharmaceuticals Plc announced that for fiscal 2013, it expects to meet the guidance of around 20% revenue growth. The Company reported revenue of $1.108 billion for fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.320 billion for fiscal 2013. 

Company Quote

2019.0
-24.0 -1.17%
9:59am EST